NCT03385395View on ClinicalTrials.gov

Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2018

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
DRUG

OctaAlpha1

For OctaAlpha1 the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions

DRUG

Glassia

For Glassia the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions

Sponsors

Lead Sponsor

Octapharma
All Listed Sponsors
lead

Octapharma

INDUSTRY

NCT03385395 - Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency | Biotech Hunter | Biotech Hunter